CLEARSIDE BIOMEDICAL INC (CLSD)
US1850631045 - Common Stock
CLEARSIDE BIOMEDICAL INC
NASDAQ:CLSD (12/20/2024, 8:02:44 PM)
After market: 0.91 +0.04 (+4.32%)0.8723
-0.06 (-6.2%)
Company Profile
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 30 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Company Info
CLEARSIDE BIOMEDICAL INC
900 North Point Parkway, Suite 200
Alpharetta GEORGIA 30005
P: 16782703631
CEO: George Lasezkay
Employees: 30
Website: https://clearsidebio.com/
CLSD News
3 days ago - Clearside Biomedical, Inc.Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, EyeALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...
a month ago - Clearside Biomedical, Inc.Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific...
a month ago - Clearside Biomedical, Inc.Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional...
2 months ago - Clearside Biomedical, Inc.Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...
2 months ago - Clearside Biomedical, Inc.Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of DirectorsALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...
2 months ago - Clearside Biomedical, Inc.Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...
CLSD Twits
Here you can normally see the latest stock twits on CLSD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
